Denali Therapeutics (DNLI) Competitor Comparison
We are evaluating the key criteria listed to compare Denali Therapeutics (DNLI) against its competitors in the Biotechnology industry.
Market Capitalization
57 / 368Gross Profits
266 / 278Total Revenue
35 / 300EBITDA
247 / 337Free Cashflow
337 / 352Quick Ratio
42 / 357Earnings per Share
249 / 359Dividend yield
0 / 6Total Cash
19 / 358Performance 3 years
146 / 368Performance 5 years
77 / 368Performance 10 years
83 / 368Linearity 3 years
83 / 368Linearity 5 years
113 / 368Linearity 10 years
61 / 368Total Rank
106 / 368Dividend Rank
107 / 368Valuation Rank
202 / 368Piotroski Rank
67 / 368Muliplier Rank
328 / 368Quick Ratio - DNLI ranking 42 / 357
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.